Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The handbook's GFR-based 2.5 mg twice-daily AF rows differ from the U.S. label's combined age, weight and serum-creatinine criteria. Dialysis evidence is limited. No combined algorithm has been generated.
Check source scope before reading a dose
AAFP - correction separating AF and VTE dose rules
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff
Source revision
2018; historical letter and author correction
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional
AAFP - correction separating AF and VTE dose rules
American Academy of Family Physicians / American Family Physician · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff Source date: 2018; historical letter and author correction Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
This historical published correction warns against applying atrial-fibrillation dose-reduction criteria to VTE treatment. The 2.5 mg twice-daily AF reduction requires at least two of: age >=80 years, weight <=60 kg, serum creatinine >=1.5 mg/dL, not one criterion. The reply explains that the manufacturer did not recommend the same reduction for VTE.
The authors emphasize limited trial data in advanced kidney disease: AMPLIFY excluded very low clearance, while dialysis recommendations relied on pharmacokinetic/pharmacodynamic information. This 2018 correction supports indication separation, not a new dialysis efficacy claim or a replacement for current labeling.
RDM30-102-apixaban-adult-1 · Source locator: AAFP - correction separating AF and VTE dose rules; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.